Holen Sie sich die Stockscreener-App
5.52
2.30%
-0.13
Handel nachbörslich:
5.51
-0.010
-0.18%
Schlusskurs vom Vortag:
$5.65
Offen:
$5.7
24-Stunden-Volumen:
43.10M
Relative Volume:
1.14
Marktkapitalisierung:
$2.36B
Einnahmen:
$64.60M
Nettoeinkommen (Verlust:
$-377.75M
KGV:
-3.5613
EPS:
-1.55
Netto-Cashflow:
$-335.64M
1W Leistung:
-8.61%
1M Leistung:
+13.11%
6M Leistung:
-1.25%
1J Leistung:
-12.66%
1-Tages-Spanne:
$5.41
$5.7356
1-Wochen-Bereich:
$5.41
$6.50
52-Wochen-Spanne:
$3.79
$12.36
Recursion Pharmaceuticals Inc Stock (RXRX) Company Profile
Firmenname
Recursion Pharmaceuticals Inc
Sektor
Branche
Telefon
(385) 269-0203
Adresse
41S RIO GRANDE STREET, SALT LAKE CITY
Vergleichen Sie RXRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RXRX
Recursion Pharmaceuticals Inc
|
5.52 | 2.47B | 64.60M | -377.75M | -335.64M | -1.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Recursion Pharmaceuticals Inc Stock (RXRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-03 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-05-22 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2023-03-16 | Eingeleitet | Needham | Buy |
| 2022-09-16 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2022-04-18 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-03-04 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2021-09-21 | Eingeleitet | Berenberg | Buy |
| 2021-05-11 | Eingeleitet | BofA Securities | Buy |
| 2021-05-11 | Eingeleitet | Goldman | Neutral |
| 2021-05-11 | Eingeleitet | JP Morgan | Neutral |
| 2021-05-11 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2021-05-11 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Recursion Pharmaceuticals Inc Aktie (RXRX) Neueste Nachrichten
Biotech Stocks To Add to Your WatchlistOctober 30th - MarketBeat
Top Biotech Stocks To Follow TodayNovember 1st - MarketBeat
Is it time to cut losses on Recursion Pharmaceuticals Inc.Quarterly Market Review & Real-Time Volume Trigger Notifications - newser.com
Can Recursion Pharmaceuticals Inc. stock hit record highs againStock Surge & Real-Time Market Sentiment Alerts - newser.com
Recursion Pharmaceuticals (RXRX) Stock: CEO Sells $5.8 Million in Shares Following Exscientia Merger - CoinCentral
Is Recursion Pharmaceuticals Inc. stock poised for growthJuly 2025 Analyst Calls & Verified Stock Trade Ideas - newser.com
Top Biotech Stocks To Keep An Eye OnOctober 28th - MarketBeat
Best Biotech Stocks To Follow TodayOctober 31st - MarketBeat
Recursion Pharmaceuticals Stock (RXRX) Opinions on Exscientia Merger and Partnerships - Quiver Quantitative
Will Recursion Pharmaceuticals Inc. stock maintain growth storyPortfolio Performance Report & Low Drawdown Momentum Trade Ideas - newser.com
Signal strength of Recursion Pharmaceuticals Inc. stock in tech scannersGlobal Markets & Free High Return Stock Watch Alerts - newser.com
Could Recursion Pharmaceuticals Be the Next Big Artificial Intelligence (AI) Stock? - The Globe and Mail
How to interpret RSI for Recursion Pharmaceuticals Inc. stockShare Buyback & AI Powered Market Entry Strategies - newser.com
Has Recursion Pharmaceuticals Inc. formed a bullish divergenceVolume Spike & Real-Time Price Movement Reports - newser.com
BMS removes 2 clinical programs from pipeline, one from Mirati and another from Exscientia - Fierce Biotech
Earnings Preview: Recursion Pharmaceuticals (RXRX) Q3 Earnings Expected to Decline - sharewise.com
How Recursion Pharmaceuticals Inc. stock reacts to bond yieldsJuly 2025 PreEarnings & Community Shared Stock Ideas - newser.com
Recursion Pharmaceuticals Incannounces Roche's exercise of option for Microglia MapSEC filing - MarketScreener
Roche Exercises Option with Recursion Pharmaceuticals - TipRanks
Recursion Pharmaceuticals Announces Roche's Option Exercise - TradingView
Published on: 2025-10-29 07:02:21 - newser.com
Recursion Pharmaceuticals (RXRX) to Release Quarterly Earnings on Wednesday - MarketBeat
What drives Recursion Pharmaceuticals Inc stock priceInsider Buying Signals & Add These Before Everyone Else Does - earlytimes.in
Recursion Pharmaceuticals (RXRX) Stock Declines While Market Improves: Some Information for Investors - sharewise.com
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
Recursion Pharmaceuticals, Inc. Experiences Evaluation Revision Amidst Market Dynamics and Performance Indicators - Markets Mojo
Recursion Pharmaceuticals (RXRX): Exploring Valuation as AI Expansion, Key Merger, and Clinical Progress Boost Interest - simplywall.st
Recursion to Report Third Quarter 2025 Business Updates and Financial Results on November 5th - MarketScreener
Recursion (NASDAQ: RXRX) to host Nov 5 (L)earnings call at 8:00 am ET, livestreamed - Stock Titan
How Recursion Pharmaceuticals Inc. stock valuations compare to rivalsJuly 2025 EndofMonth & Reliable Price Breakout Alerts - newser.com
IQ EQ FUND MANAGEMENT IRELAND Ltd Boosts Holdings in Recursion Pharmaceuticals, Inc. $RXRX - MarketBeat
Sumitomo Mitsui Trust Group Inc. Reduces Stock Position in Recursion Pharmaceuticals, Inc. $RXRX - MarketBeat
Will Recursion Pharmaceuticals Inc. stock benefit from sector rotationJuly 2025 Setups & Smart Investment Allocation Tips - fcp.pa.gov.br
Recursion Pharmaceuticals Inc. stock volume spike explainedJuly 2025 Weekly Recap & Real-Time Chart Pattern Alerts - newser.com
When is the best time to exit Recursion Pharmaceuticals Inc.2025 Sector Review & Daily Oversold Bounce Ideas - newser.com
Is Recursion Pharmaceuticals Inc. stock a top momentum play2025 Big Picture & Capital Protection Trade Alerts - Fundação Cultural do Pará
Recursion Pharmaceuticals (RXRX) Drops on 3rd Day as Company Execs Dispose of Shares - MSN
Finanzdaten der Recursion Pharmaceuticals Inc-Aktie (RXRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.62%
0.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):